Compare PCVX & HQY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCVX | HQY |
|---|---|---|
| Founded | 2013 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 7.1B |
| IPO Year | 2020 | 2014 |
| Metric | PCVX | HQY |
|---|---|---|
| Price | $56.05 | $89.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 15 |
| Target Price | $109.00 | ★ $119.33 |
| AVG Volume (30 Days) | ★ 1.2M | 738.9K |
| Earning Date | 11-03-2026 | 08-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 125.69 |
| EPS | N/A | ★ 1.60 |
| Revenue | N/A | ★ $229,525,000.00 |
| Revenue This Year | N/A | $7.86 |
| Revenue Next Year | N/A | $7.68 |
| P/E Ratio | ★ N/A | $54.47 |
| Revenue Growth | N/A | ★ 28.68 |
| 52 Week Low | $39.87 | $72.76 |
| 52 Week High | $65.00 | $107.62 |
| Indicator | PCVX | HQY |
|---|---|---|
| Relative Strength Index (RSI) | 44.39 | 35.30 |
| Support Level | $52.18 | $83.35 |
| Resistance Level | $58.77 | $89.13 |
| Average True Range (ATR) | 2.19 | 2.26 |
| MACD | -0.27 | -0.40 |
| Stochastic Oscillator | 30.24 | 24.86 |
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.